Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis.

  title={Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis.},
  author={Takashi Wada and Kengo Furuichi and Norihiko Sakai and Yasunori Iwata and Kiyoki Kitagawa and Yuko Ishida and Toshikazu Kondo and Hiroyuki Hashimoto and Yoshiro Ishiwata and Naofumi Mukaida and Naohisa Tomosugi and Kouji Matsushima and Kensuke Egashira and Hitoshi Yokoyama},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={15 4},
Monocyte chemoattractant protein (MCP)-1, also termed monocyte chemotactic and activating factor (MCAF)/CCL2, plays an important role in progressive organ fibrosis. It was hypothesized that MCP-1, through its cognate receptor, CCR2, regulates the pathogenesis and is therapeutically of importance for renal fibrosis. To achieve this goal, the therapeutic efficacy and efficiency in renal fibrosis induced by a unilateral ureteral obstruction nephropathy model in mice by the blockade of MCP-1/CCR2… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 80 extracted citations


Publications referenced by this paper.
Showing 1-10 of 34 references

Chemokines as the therapeutic targets for renal diseases

  • T Wada, K Matsushima, H Yokoyama
  • Curr Med Chem AntiInflammatory Anti-Allergy
  • 2003
1 Excerpt

Similar Papers

Loading similar papers…